͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
| | | | The Great Debates series is back! Join us in Portland, USA, this October as leaders in the early detection and diagnosis research community go head-to-head on two of the biggest challenges facing the field right now.
Which side of each Great Debate will you choose – and will our debaters change your mind?
Read on below and find out who this year’s debaters are. |
| | |
|
|
|
|
|
| | Looking back: the many adventures of a promising ADC |
| | Myricx Bio were honoured with the Start-up Achievement Recognition Award at last week's Cancer Research Horizons Innovation and Entrepreneurship Awards. Though this isn't the first we've heard of their exciting work, so we’re winding back the clock to revisit the last time we spoke to Ed Tate, Myricx Bio Co-founder and Chairman of its Scientific Advisory Board.
We’re busy celebrating their accomplishments, but Ed knows it’s a winding path to successful clinical development. We interviewed him about founding the company and its approach to developing first-in-class N-myristoyltransferase (NMT) inhibitors as antibody-drug conjugate payloads.
NMT isn’t an obvious oncology target; it isn’t highly regulated, it isn’t mutated and it doesn’t drive specific cancers. But Ed saw an opportunity to advance an NMT inhibitor as an oncology drug. Ed and his collaborators have continued to explore this and are advancing into clinical testing.
|
| | |
|
|
|---|
|
|
|
|
|
| | Great Debate 1: The randomized control trial of cancer screening is dead |
| | | | |
|
|
|
Great Debate 2: Early detection of cancer doesn’t change lifespan |
| | | | |
|
|
|
Get involved in the action at this year’s Early Detection of Cancer Conference, taking place from 21 to 23 October in Portland, USA. Register now to secure your seat. |
| | |
|
|
|
Join the Childhood Cancer Conference 2025 |
| Children with Cancer UK are hosting their 2025 research conference, taking place on 24-25 November in Birmingham with the theme “Embracing research and impact”. The two-day event brings together scientists, clinicians, patient families, funders and industry partners to share knowledge, spark collaboration and showcase real-world impact.
Hear keynote talks from Louis Chesler (Institute of Cancer Research London), Chris Halsey (University of Glasgow), Steven Clifford (Newcastle University) and Kathy Prichard-Jones (University College London) discussing progress and outputs from their research.
Register by 1 August to secure a discounted ticket. You can also submit an abstract for a poster presentation, and, if you're an early career researcher, apply for an oral presentation slot. |
| | |
|
|
|
Calling all early career oncologists – join us at MAP 2025 |
| For early career oncologists, the Molecular Analysis for Precision Oncology Congress 2025 offers a valuable opportunity to engage with the latest developments in precision oncology.
Mireia Crispin (Early Cancer Institute), Pawel Sobczuk (Vall d’Hebron Intitute of Oncology), Emre Kocakavuk (Universitätsmedizin Essen) and Arsela Prelaj (Istituto Nazionale Tumori di Milano) share their perspectives on what makes this congress particularly relevant for those at the start of their research careers. From thoughtfully designed sessions to career development and networking opportunities, the event is tailored to support professional growth in a rapidly evolving field.
Hear directly from them about why the congress is worth attending. |
| | |
|
|
|
Funding & research opportunities |
| Get in touch with our office for confidential advice on eligibility, remit and funding options prior to applying. |
|
| | | | | | | | | | | | | | | | Applications accepted year round |
|
|---|
|
| | |
|
|
| | Together we are
beating cancer |
| | |
|---|
|
|
|
| | | You are playing a crucial role in helping us beat cancer, so we'd like to continue to keep you updated on what we're up to. You can manage your preferences and unsubscribe here.
Your details are safe with us. Check out our Privacy Policy.
Our supporters are at the heart of everything we achieve at Cancer Research UK. Read our Fundraising Promise.
This email is from Cancer Research UK. Cancer Research UK is a registered charity in England and Wales (1089464), Scotland (SC041666), the Isle of Man (1103) and Jersey (247). A company limited by guarantee. Registered company in England and Wales (4325234) and the Isle of Man (5713F). Registered address: 2 Redman Place, London, E20 1JQ. |
|
|
|
